Welcome to our dedicated page for Genfit S.A. SEC filings (Ticker: GNFT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GENFIT S.A. (GNFT) files as a foreign private issuer with the U.S. Securities and Exchange Commission, primarily using Form 20-F for its annual report and Form 6-K for current reports. These filings provide insight into the company’s biopharmaceutical activities in severe chronic liver diseases, including primary biliary cholangitis (PBC) and acute-on-chronic liver failure (ACLF).
On this page, you can review GENFIT’s Form 6-K submissions, which frequently include press releases and financial documents such as Half-Year Business and Financial Reports. Several 6-K filings explicitly state that their contents, including attached exhibits, are incorporated by reference into GENFIT’s registration statements on Form F-3 and Form S-8. This linkage shows how operational and clinical updates feed into the company’s broader capital markets and employee equity plans.
GENFIT’s filings often discuss its late-stage clinical programs, such as the ELATIVE™ Phase III trial of elafibranor in PBC, as well as its strategic licensing agreements. Examples include the exclusive worldwide license granted to Ipsen for elafibranor in PBC and the out-licensing agreement with Seal Rock Therapeutics for the development of an injectable formulation of SRT-015 for ACLF. These documents help investors understand the contractual framework, milestone structures, and royalty arrangements around GENFIT’s pipeline.
Stock Titan’s platform enhances access to these materials by offering real-time updates from EDGAR and AI-powered summaries that explain the key points of lengthy reports. Users can quickly identify important disclosures in annual reports on Form 20-F, current reports on Form 6-K, and other incorporated documents, making it easier to assess GENFIT’s regulatory, clinical, and financial disclosures without reading every page in detail.
GENFIT S.A. furnished a Form 6-K as a foreign private issuer to provide its Half-Year Business and Financial Report for the period ended June 30, 2025, attached as Exhibit 99.1. The report itself contains the detailed business and financial information.
The company also states that this Form 6-K, including Exhibit 99.1, is incorporated by reference into its existing registration statements on Form F-3 and Form S-8 and their related prospectuses from the filing date, unless later filings supersede it.
GENFIT S.A. furnished a Form 6-K as a foreign private issuer, mainly to attach a press release dated September 22, 2025 as Exhibit 99.1. The company also made this report part of its existing Form F-3 and Form S-8 registration statements by incorporating it by reference. The filing was signed by Chief Executive Officer Pascal Prigent.